Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-101 in Healthy Subjects and Subjects With Chronic HBV Infection
NCT05960240Phase 1Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of zabalafin in Chronic Hepatitis B (CHB) (3 arms), sponsored by Arbutus Biopharma Corporation. Primary endpoints: Incidence of adverse events, serious AEs, immune related AEs and discontinuations at 196 days, Incidence of clinically significant laboratory abnormalities at 196 days and 1 more. Started Aug 2023; status: completed.
02
Drugs
zabalafin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05960240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960240.